FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124936866> ?p ?o ?g. }

• W2124936866 endingPage "280" @default.
• W2124936866 startingPage "274" @default.
• W2124936866 abstract "Abstract: This phase I/II trial investigates the safety and feasibility of six cycles of concurrent taxane, anthracycline and cyclophosphamide on a dose dense schedule. Patients with stage II/III breast cancer were treated with docetaxel (T) 75 mg/m2, epirubicin (E) 75 mg/m2 (cohort 1, n = 3) or 100 mg/m2 (cohort 2, n = 12), and cyclophosphamide (C) 500 mg/m2 IV on day 1, with pegfilgrastim 6 mg subcutaneously on day 2, every 2 weeks for six cycles. Patients were assessed for toxicity every 2 weeks; cardiac function and response (if neoadjuvant) were assessed after six cycles. All patients in cohort 1 received 100% planned dose intensity; in cohort 2, five of twelve patients received 100% and 11/12 received >80%. There were no dose reductions or delays for day 1 myelotoxicity. Dose reductions as a result of febrile neutropenia (FN) occurred in cohort 2, with six of twelve patients experiencing FN in seven of sixty-nine cycles. Six patients had anemia ≥grade 3; five received RBC transfusion and seven received an erythropoietic growth factor. Four patients required dose reductions for nonhematologic toxicity (two mucositis; one neurotoxicity; one diarrhea + cellulitis). Four patients developed thrombophlebitis, which was associated with FN in one of four. Two of fourteen evaluable patients had asymptomatic decreases in LVEF >10%; all remained within normal range. All four patients receiving neoadjuvant TEC had significant clinical responses (one CR, three PR). No pathologic CRs were seen. Conclusions: Dose dense TEC chemotherapy is feasible, has acceptable toxicity at doses equivalent to TAC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2), and has moderate but manageable toxicity using a higher epirubicin dose of 100 mg/m2, with FN occurring in six of twelve patients at the higher dose." @default.
• W2124936866 created "2016-06-24" @default.
• W2124936866 creator A5004931108 @default.
• W2124936866 creator A5007726590 @default.
• W2124936866 creator A5008216010 @default.
• W2124936866 creator A5013149664 @default.
• W2124936866 creator A5027768313 @default.
• W2124936866 creator A5063968442 @default.
• W2124936866 creator A5071214833 @default.
• W2124936866 date "2007-05-01" @default.
• W2124936866 modified "2023-09-24" @default.
• W2124936866 title "Phase I/II Trial of Adjuvant Dose-Dense Docetaxel/Epirubicin/Cyclophosphamide (TEC) in Stage II and III Breast Cancer" @default.
• W2124936866 cites W1848579801 @default.
• W2124936866 cites W1961026612 @default.
• W2124936866 cites W1970797634 @default.
• W2124936866 cites W1975854376 @default.
• W2124936866 cites W1988470760 @default.
• W2124936866 cites W2027906728 @default.
• W2124936866 cites W2051213632 @default.
• W2124936866 cites W2068132070 @default.
• W2124936866 cites W2075213874 @default.
• W2124936866 cites W2096850750 @default.
• W2124936866 cites W2098333537 @default.
• W2124936866 cites W2098344328 @default.
• W2124936866 cites W2101760255 @default.
• W2124936866 cites W2128822091 @default.
• W2124936866 cites W2133764807 @default.
• W2124936866 cites W2135800076 @default.
• W2124936866 cites W2138734774 @default.
• W2124936866 cites W2139248078 @default.
• W2124936866 cites W2139510434 @default.
• W2124936866 cites W2162760540 @default.
• W2124936866 cites W2265230738 @default.
• W2124936866 cites W2269955197 @default.
• W2124936866 cites W2589790661 @default.
• W2124936866 cites W4234837271 @default.
• W2124936866 doi "https://doi.org/10.1111/j.1524-4741.2007.00421.x" @default.
• W2124936866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17461902" @default.
• W2124936866 hasPublicationYear "2007" @default.
• W2124936866 type Work @default.
• W2124936866 sameAs 2124936866 @default.
• W2124936866 citedByCount "11" @default.
• W2124936866 countsByYear W21249368662014 @default.
• W2124936866 countsByYear W21249368662015 @default.
• W2124936866 countsByYear W21249368662021 @default.
• W2124936866 countsByYear W21249368662023 @default.
• W2124936866 crossrefType "journal-article" @default.
• W2124936866 hasAuthorship W2124936866A5004931108 @default.
• W2124936866 hasAuthorship W2124936866A5007726590 @default.
• W2124936866 hasAuthorship W2124936866A5008216010 @default.
• W2124936866 hasAuthorship W2124936866A5013149664 @default.
• W2124936866 hasAuthorship W2124936866A5027768313 @default.
• W2124936866 hasAuthorship W2124936866A5063968442 @default.
• W2124936866 hasAuthorship W2124936866A5071214833 @default.
• W2124936866 hasBestOaLocation W21249368661 @default.
• W2124936866 hasConcept C121608353 @default.
• W2124936866 hasConcept C126322002 @default.
• W2124936866 hasConcept C141071460 @default.
• W2124936866 hasConcept C2776694085 @default.
• W2124936866 hasConcept C2776755627 @default.
• W2124936866 hasConcept C2776802502 @default.
• W2124936866 hasConcept C2777063308 @default.
• W2124936866 hasConcept C2778496288 @default.
• W2124936866 hasConcept C2778658803 @default.
• W2124936866 hasConcept C2778850193 @default.
• W2124936866 hasConcept C2780835546 @default.
• W2124936866 hasConcept C2781190966 @default.
• W2124936866 hasConcept C530470458 @default.
• W2124936866 hasConcept C71924100 @default.
• W2124936866 hasConcept C72563966 @default.
• W2124936866 hasConcept C90924648 @default.
• W2124936866 hasConceptScore W2124936866C121608353 @default.
• W2124936866 hasConceptScore W2124936866C126322002 @default.
• W2124936866 hasConceptScore W2124936866C141071460 @default.
• W2124936866 hasConceptScore W2124936866C2776694085 @default.
• W2124936866 hasConceptScore W2124936866C2776755627 @default.
• W2124936866 hasConceptScore W2124936866C2776802502 @default.
• W2124936866 hasConceptScore W2124936866C2777063308 @default.
• W2124936866 hasConceptScore W2124936866C2778496288 @default.
• W2124936866 hasConceptScore W2124936866C2778658803 @default.
• W2124936866 hasConceptScore W2124936866C2778850193 @default.
• W2124936866 hasConceptScore W2124936866C2780835546 @default.
• W2124936866 hasConceptScore W2124936866C2781190966 @default.
• W2124936866 hasConceptScore W2124936866C530470458 @default.
• W2124936866 hasConceptScore W2124936866C71924100 @default.
• W2124936866 hasConceptScore W2124936866C72563966 @default.
• W2124936866 hasConceptScore W2124936866C90924648 @default.
• W2124936866 hasIssue "3" @default.
• W2124936866 hasLocation W21249368661 @default.
• W2124936866 hasLocation W21249368662 @default.
• W2124936866 hasOpenAccess W2124936866 @default.
• W2124936866 hasPrimaryLocation W21249368661 @default.
• W2124936866 hasRelatedWork W1972716219 @default.
• W2124936866 hasRelatedWork W1973296353 @default.
• W2124936866 hasRelatedWork W2001597364 @default.
• W2124936866 hasRelatedWork W2031406601 @default.
• W2124936866 hasRelatedWork W2122468945 @default.
• W2124936866 hasRelatedWork W2242484054 @default.

• next